The Medicines Company today announced the withdrawal of the European marketing authorization application (MAA) for the 200mg 3-7 day daily dose therapy of oritavancin, its investigational antibiotic drug candidate for the treatment of complicated skin and skin structure infections (cSSSI) caused by gram positive pathogens.
The details can be read here.
No comments:
Post a Comment